A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients
Adv Ther. 2016 Mar 12. DOI 10.1007/s12325-016-0312-y
Biologics are used to treat several inflammatory diseases, including RA, PsO, PsA, and AS; however, the cost of biologic therapies is high compared to non-biologic DMARDs. By using evidence-based assessment of comparative costs between biologics, healthcare resources can be properly allocated. This study used medical and pharmacy claims data to assess the utilitisation and cost of biologic treatment for RA, PsO, PsA, and AS. ETN (45%), ADA (32%), and INF (9%) were the most common medications and...